Indicated for: leukemia
Route of administration: injectable
Substance: daunorubicin (antineoplastic agent)
ATC: L01DB02 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)
Daunorubicinum is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division.
The medication is administered intravenously and is often used in combination with other chemotherapy drugs to enhance treatment effectiveness. It is effective in inducing remission in patients with acute leukemia.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, it may cause cardiac toxicity. Close monitoring is essential during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Daunorubicinum. Follow all medical recommendations to minimize associated risks.